“We are honored to welcome the Bob’s Last Marathon podcast to Penn Memory Center. We are committed to continuing its legacy by expanding access to crucial information and support for our patients and caregivers." Jason Karlawish, MD https://t.co/3Zhcxt1ndj

Lena celebrates the 75th episode of the podcast and recounts the significant strides in the field on many fronts—diagnosis, treatment, and importantly, caregiving. https://t.co/3Zhcxt1ndj Browse by category: https://t.co/B5phWsm5s1 https://t.co/wtsY0fndK8 #PennMemoryCenter

“I see Steve in my children, and theirs. I find him in the stars and feel him in the gentle winds.” —Judy Johanson https://t.co/C6QCzxVzrA Browse by category: https://t.co/B5phWsm5s1 https://t.co/wtsY0fndK8 #bobsmarathon #alzheimers #alzheimerssupport #dementiacare #dementia

Two caregivers share their stories in this episode: Judith Johanson and Katie Brandt, both at Massachusetts General Hospital. https://t.co/C6QCzxVzrA Browse by category: https://t.co/B5phWsm5s1 https://t.co/wtsY0fndK8 #bobsmarathon #alzheimers #alzheimerssupport #dementiacare

“The greatest surprise was when I realized that grief, love, and joy could exist together in one heart: mine.” —Katie Brandt https://t.co/C6QCzxVzrA Browse by category: https://t.co/U1cdJezobS https://t.co/wtsY0fndK8 #bobsmarathon #alzheimers #alzheimerssupport #dementiacare

What happens when we reach the end of our journey, when we are confronted with grief and loss, while the burden of caregiving is relieved? In this episode, two caregivers share their stories. https://t.co/C6QCzxVzrA Browse by category: https://t.co/B5phWsm5s1

“The greatest promise of blood-based biomarkers may be in the prevention of Alzheimer’s disease.” —Dr. Steven E. Arnold https://t.co/1ThwOmfESl Browse by category: https://t.co/B5phWsm5s1 https://t.co/wtsY0fndK8 #bobsmarathon #alzheimers #alzheimerssupport #dementiacare #dementia

Faster, less expensive, and more accessible blood-based biomarkers, a long-standing goal for the medical research community, are now on the horizon. https://t.co/1ThwOmfESl Browse by category: https://t.co/B5phWsm5s1 https://t.co/wtsY0fndK8 #bobsmarathon #alzheimers

“We are now moving into a new era of treatment and prevention of Alzheimer’s disease.” — Dr. Steven E. Arnold https://t.co/WE1qSVrEsR Browse by category: https://t.co/J6Wsc4mF4U https://t.co/wtsY0fmFUA #bobsmarathon #alzheimers #alzheimerssupport #dementiacare #dementia

With the availability of anti-amyloid treatments for Alzheimer’s disease,, easier, less expensive, and more accessible blood-based biomarkers to correctly diagnose and stage the disease become ever more important.  https://t.co/WE1qSVrEsR

“I like to frame what we have today as a huge scientific advance but a modest clinical advance.” —Dr. Steven E. Arnold https://t.co/0kMMVutt1x Browse category: https://t.co/B5phWsm5s1 https://t.co/wtsY0fndK8 #bobsmarathon #alzheimers #alzheimerssupport #dementiacare #dementia

While clinical trials demonstrated the ability of Leqembi (lecanemab) to clear amyloid levels, there is still cognitive decline. https://t.co/0kMMVutt1x Browse episodes by category: https://t.co/B5phWsm5s1 https://t.co/wtsY0fndK8 #bobsmarathon #alzheimers #alzheimerssupport

“It ultimately comes down to conversations between patients and their physician and families in terms of acceptable levels of risk.” —Dr. Steven E. Arnold https://t.co/0kMMVutt1x https://t.co/wtsY0fndK8 #bobsmarathon #alzheimers #alzheimerssupport #dementiacare #dementia

Genetic status can impact both potential benefit and risk in anti-amyloid therapy. The apolipoprotein E4 gene, for example, is a risk gene for both Alzheimer’s disease and side effects associated with Leqembi (lecanemab). https://t.co/0kMMVutt1x

“We are very much trying to keep to the way the clinical trials were designed in terms of who we feel is appropriate for the drug.” —Dr. David A. Wolk https://t.co/0kMMVutt1x Browse by category: https://t.co/B5phWsm5s1 #bobsmarathon #alzheimers #alzheimerssupport #dementiacare

Early experience with Leqembi (lecanemab) gives clinicians insight into the challenges of administering this newly approved therapy as well as the benefits.  https://t.co/pEkEkr3KTk Browse by category: https://t.co/J6Wsc4mF4U

“It has taken us decades and numerous failures of different treatments and billions of dollars of clinical trials to come to the point that we are now at.” —Dr. Steven E. Arnold https://t.co/m8NrMNvOeJ Browse by category: https://t.co/B5phWslxCt

Two leading clinicians explain a key feature of new anti-amyloid therapies—that they are designed to attack oligomers rather than single protein molecules—and why this makes a difference in clinical efficacy. https://t.co/m8NrMNvOeJ Browse by category: https://t.co/B5phWslxCt

“There was clear evidence of slowing of progression of the disease over the 18-month period and that’s the kind of definitive data that led the FDA to approve the drug.” —Dr. David A. Wolk https://t.co/m8NrMNwm4h Browse by category: https://t.co/B5phWsm5s1 #alzheimers #icym

Data from the 18-month multicenter clinical trial that was pivotal to the approval of Leqembi (lecanemab) demonstrated both a reduction in amyloid burden and slowing progression of cognitive decline. https://t.co/m8NrMNwm4h Browse by category: https://t.co/B5phWsm5s1